Guardian Pharmacy Services, Inc. Class A (GRDN) AI Stock Analysis

• Market Cap: $1.34B
• Dividend Yield: N/A
• Average Volume (3M): 294.94K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.55
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 3,400
• Sector: Healthcare
• Sector Strength: 55
• Industry: Medical - Distribution
• EPS (TTM): 0.15
• Shares Outstanding: 24,160,393
• 10 Day Avg. Volume: 323,271
• 30 Day Avg. Volume: 294,937
• PEG Ratio: -1.24
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 17.30
• Enterprise Value/Market Cap: 0.77
• Enterprise Value/Revenue: 0.34
• Enterprise Value/Gross Profit: 5.33
• Enterprise Value/Ebitda: -6.34
• 1Y Price Target: $28.00
• Price Target Upside: 38.89% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 47 Neutral
• Price Target: ―

Guardian Pharmacy Services, Inc. presents a mixed picture. Strong revenue growth and positive guidance improve the outlook, yet significant profitability and leverage challenges remain. The technical analysis signals a short-term upward trend, but valuation is difficult to assess due to missing key metrics. Overall, the stock's strengths in growth are countered by financial and valuation uncertainties, resulting in a moderate stock score.

Guardian Pharmacy Services, Inc. Class A Business Overview & Revenue Model

Company Description

Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.

How the Company Makes Money

Guardian Pharmacy Services, Inc. generates revenue primarily through the provision of pharmacy services to long-term care and senior living facilities. The company earns money by supplying medications directly to these institutions, where they are responsible for managing the pharmaceutical needs of residents. Key revenue streams include the sale of prescription drugs, consulting services for medication management, and specialized packaging solutions that ensure compliance with healthcare regulations. Significant partnerships with healthcare institutions and insurance providers also contribute to its earnings by facilitating a steady client base and enhancing service delivery. Additionally, GRDN may receive reimbursements from government programs and private insurance for medications dispensed to covered individuals.

Guardian Pharmacy Services, Inc. Class A Financial Statement Overview

Summary

Guardian Pharmacy Services, Inc. faces profitability and leverage challenges. The company has shown positive revenue growth, but operational inefficiencies have led to recent losses. The absence of equity highlights financial risks, yet stable cash flows provide some operational reassurance. Strategic adjustments are needed to improve profitability and balance sheet strength.

Income Statement

Gross profit margin has remained relatively stable while revenue growth has been positive over the years. However, the company faced significant challenges in the latest year, with negative EBIT and net income, highlighting operational inefficiencies and profitability issues.

Balance Sheet

The balance sheet shows high leverage with no stockholders' equity for the past years, indicating significant financial risk. The debt-to-equity ratio cannot be calculated due to zero equity, suggesting potential solvency concerns.

Cash Flow

The company managed to maintain positive operating and free cash flows, indicating decent cash management. However, the free cash flow growth rate is inconsistent, and the reliance on cash flow to sustain operations due to negative net income is a concern.

Breakdown
Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement		Total Revenue
1.23B	1.05B	908.91M	792.07M	735.96M
	Gross Profit
244.37M	208.31M	185.87M	161.26M	147.00M
	EBIT
-62.92M	40.95M	51.99M	30.15M	32.06M
	EBITDA
-43.43M	58.81M	68.15M	46.49M	49.07M
	Net Income Common Stockholders
-87.29M	23.90M	35.42M	16.31M	19.94M
Balance Sheet		Cash, Cash Equivalents and Short-Term Investments
4.66M	752.00K	607.00K	15.01M	6.45M
	Total Assets
320.81M	271.17M	256.11M	235.85M	217.87M
	Total Debt
30.13M	61.00M	56.81M	50.43M	58.84M
	Net Debt
25.47M	60.25M	56.21M	35.41M	52.39M
	Total Liabilities
170.83M	211.31M	180.19M	182.53M	150.80M
	Stockholders Equity
142.67M	0.00	0.00	0.00	0.00
Cash Flow		Free Cash Flow
41.59M	56.26M	31.75M	49.22M	44.27M
	Operating Cash Flow
57.96M	70.82M	48.52M	58.50M	52.61M
	Investing Cash Flow
-30.41M	-13.44M	-17.90M	-13.15M	-12.18M
	Financing Cash Flow
-23.64M	-57.23M	-45.03M	-36.79M	-34.26M

Guardian Pharmacy Services, Inc. Class A Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HSIC	74 Outperform	$8.69B	22.11	11.78%	―	1.75%	8.76%
PBH	74 Outperform	$4.21B	19.87	12.30%	―	1.10%	2.65%
PDCO	70 Outperform	$2.77B	20.21	14.15%	2.49%	-0.85%	-23.40%
CAH	70 Outperform	$36.64B	23.98	-43.80%	1.32%	0.78%	183.45%
Sector *	54 Neutral	$5.38B	3.31	-45.11%	3.29%	16.82%	0.04%
OMI	48 Neutral	$601.42M	―	-49.91%	―	2.84%	-828.91%
GRDN	47 Neutral	$1.34B	―		―	―	―

Guardian Pharmacy Services, Inc. Class A Corporate Events

Guardian Pharmacy Sets 2025 Incentive Performance Targets

On March 24, 2025, Guardian Pharmacy Services, Inc. announced the establishment of performance criteria and targets for its 2025 annual cash incentive awards under the 2024 Equity and Incentive Compensation Plan. The performance metrics include company revenue, adjusted EBITDA, and geographic expansion, with varying weightings. Executive officers have specific payout ranges based on achieving threshold, target, and maximum performance goals, impacting their potential earnings for the year.

Guardian Pharmacy Services Reports Strong Q4 2024 Results

Guardian Pharmacy Services, Inc. announced preliminary unaudited financial results for Q4 and full year 2024, showing a strong performance with a 20.5% increase in Q4 revenue driven by organic growth, acquisitions, and increased vaccinations. Despite a decrease in net income due to tax provisions and share-based compensation expenses, the company reported a 30.3% increase in adjusted EBITDA. Guardian provided 2025 guidance with expected revenue between $1.330 billion and $1.350 billion, and adjusted EBITDA between $97.0 million and $101.0 million, indicating a positive outlook for the coming year.